Who are in the management team of Fabino Enter?

As of March 2023, the management team of Fabino Enter includes Atul Jain (CMD & Executive Director), Aditya Mahavir Jain (Executive Director & Wholetime Director), Arihant Jain (Non-Executive Director), Tesu Alakh (Independent Non-Executive Director), Gagan Gupta (Independent Non-Executive Director), and Sumit Malik (Non-Executive & Non-Independent Director). These individuals oversee the company's governance and strategic direction.

As of March 2023, the management team of Fabino Enter includes the following individuals:<BR><BR>1. Atul Jain - CMD & Executive Director<BR>2. Aditya Mahavir Jain - Executive Director & Wholetime Director<BR>3. Arihant Jain - Non-Executive Director<BR>4. Tesu Alakh - Independent Non-Executive Director<BR>5. Gagan Gupta - Independent Non-Executive Director<BR>6. Sumit Malik - Non-Executive & Non-Independent Director<BR><BR>These members form the board of directors, contributing to the governance and strategic direction of the company.

Has Fabino Enter declared dividend?

No Dividend History Available

Who are the peers of the Fabino Enter?

Fabino Enter's peers include Unjha Formul., Beryl Drugs, Cian Healthcare, Adline Chem Lab, Ortin Global, Vivanza Biosci., Ganga Pharma., Brawn Biotech, and Shyama Computro. Unjha Formul. shows excellent management risk and the highest 1-year return at 23.34%, while Fabino Enter has average management risk and a 1-year return of -12.24%.

Peers: The peers of Fabino Enter are Unjha Formul., Beryl Drugs, Cian Healthcare, Adline Chem Lab, Ortin Global, Vivanza Biosci., Ganga Pharma., Brawn Biotech, Shyama Computro.<BR><BR>Quality Snapshot: Excellent management risk is observed at Unjha Formul., while Average management risk is found at Fabino Enter and the rest. Below Average management risk is noted for Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and Brawn Biotech. Adline Chem Lab and Shyama Computro. do not qualify for management risk assessment. Growth is Below Average for Fabino Enter, Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and Brawn Biotech, while Adline Chem Lab and Shyama Computro. do not qualify. Capital Structure is Good at Unjha Formul., Average at Fabino Enter, and Below Average for Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and Brawn Biotech, with Adline Chem Lab and Shyama Computro. not qualifying.<BR><BR>Return Snapshot: Unjha Formul. has the highest 1-year return at 23.34%, while Cian Healthcare has the lowest at -81.16%. Fabino Enter's 1-year return is -12.24%, which is better than Cian Healthcare but worse than Unjha Formul. Additionally, Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and Brawn Biotech all have negative six-month returns.

What does Fabino Enter do?

Fabino Enterprises Ltd is a micro-cap pharmaceutical company, incorporated in 2011, with recent net sales of 11 Cr and a market cap of 6 Cr. It has a P/E ratio of 5.00 and a debt-equity ratio of 0.20.

Overview:<BR>Fabino Enterprises Ltd is a growing pharmaceutical company operating in the Micro Cap category within the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>Fabino Enterprises Ltd was incorporated as "Fabino Life Sciences Private Limited" in 2011 and later converted to a Public Limited Company, changing its name to "Fabino Life Sciences Limited" in 2015. The most recent quarterly results reported net sales and net profit for June 2021.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 11 Cr (Quarterly Results - Jun 2021) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2021) <BR>Market-cap value: INR 6 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 5.00 <BR>Industry P/E: N/A <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.20 <BR>Return on Equity: 3.13% <BR>Price to Book: 1.35 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

Who are the top shareholders of the Fabino Enter?

The top shareholder of Fabino Enter is promoter Aditya Mahavir Jain, holding 52.38%. The highest public shareholder is Nopea Capital Services Private Limited at 4.71%, while individual investors collectively own 29.18% of the shares.

The top shareholders of Fabino Enter include Aditya Mahavir Jain, who is the promoter with the highest holding at 52.38%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors currently do not hold any shares in the company. The highest public shareholder is Nopea Capital Services Private Limited, holding 4.71%. Additionally, individual investors collectively hold 29.18% of the shares.

How big is Fabino Enter?

As of 18th July, Fabino Enterprises Ltd has a market capitalization of 5.00 Cr, with recent net sales of 1.13 Cr and a net profit of 0.01 Cr for the quarter ending June 2021. The balance sheet for March 2024 shows shareholder's funds of 4.14 Cr and total assets of 15.35 Cr.

As of 18th July, Fabino Enterprises Ltd has a market capitalization of 5.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest quarter ending June 2021, Fabino Enterprises Ltd reported Net Sales of 1.13 Cr and a Net Profit of 0.01 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 4.14 Cr and Total Assets of 15.35 Cr.

Is Fabino Enter overvalued or undervalued?

As of October 8, 2025, Fabino Enter is considered very expensive and overvalued, with a PE ratio of 4.83 and disappointing financial performance, including a year-to-date stock return of -30.09%, compared to the Sensex's 4.65% return.

As of 8 October 2025, the valuation grade for Fabino Enter has moved from risky to very expensive. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 4.83, an EV to EBIT of 6.22, and a ROE of 3.03%. In comparison to its peers, Fabino Enter's PE ratio is significantly lower than Sun Pharma's 34.13 and Divi's Lab's 70.37, indicating that it is trading at a discount relative to these competitors despite its high valuation grade.<BR><BR>Fabino Enter's financial performance has been disappointing, as evidenced by a year-to-date stock return of -30.09%, contrasting sharply with the Sensex's positive return of 4.65% over the same period. This underperformance, combined with its very expensive valuation grade and low profitability ratios, further supports the conclusion that the company is overvalued in the current market environment.

When is the next results date for Fabino Enter?

The next results date for Fabino Enter is 13 November 2025.

The next results date for Fabino Enter is scheduled for 13 November 2025.

How has been the historical performance of Fabino Enter?

Fabino Enter's historical performance shows stable share capital and gradual increases in total reserves and shareholder's funds, but significant growth in long-term borrowings and total liabilities, with no reported profit or cash flows, indicating a lack of operational profitability. The book value per share slightly increased from Rs 19.59 to Rs 20.02 over the period.

Answer:<BR>The historical performance of Fabino Enter shows a consistent trend in its financial metrics over the past three years.<BR><BR>Breakdown:<BR>Fabino Enter's share capital has remained stable at Rs 2.10 crore from March 2023 to March 2025. Total reserves have shown a gradual increase, rising from Rs 2.01 crore in March 2023 to Rs 2.10 crore in March 2025. Shareholder's funds also increased slightly, from Rs 4.11 crore in March 2023 to Rs 4.20 crore in March 2025. Long-term borrowings have significantly increased, moving from Rs 0.41 crore in March 2023 to Rs 1.79 crore in March 2025, primarily due to an increase in unsecured loans. Total liabilities have risen sharply from Rs 5.00 crore in March 2023 to Rs 17.65 crore in March 2025, reflecting higher trade payables, which increased from Rs 0.37 crore to Rs 11.42 crore over the same period. Total assets have also grown, from Rs 5.00 crore in March 2023 to Rs 17.65 crore in March 2025, with total current assets increasing from Rs 4.78 crore to Rs 17.03 crore. However, the company has reported no profit before tax or cash flows from operating, investing, or financing activities during these years, indicating a lack of operational profitability. The book value per share has seen a slight increase from Rs 19.59 in March 2023 to Rs 20.02 in March 2025.

Which are the latest news on Fabino Enter?

Why is Fabino Enter falling/rising?

As of 17-Nov, Fabino Enterprises Ltd is priced at Rs 23.00, with a year-to-date decline of -30.09% and underperformance compared to the Sensex, which has gained 8.72%. The stock is trading below all moving averages and has shown inconsistent investor interest, indicating a bearish trend.

As of 17-Nov, Fabino Enterprises Ltd is currently priced at Rs 23.00, showing no change (0.00%). The stock has underperformed today, opening with a loss of -5.15% and touching an intraday low of Rs 23. It is also close to its 52-week low, just 0.87% away from Rs 22.8. Over the past week and month, the stock has not changed in price, while its year-to-date performance reflects a significant decline of -30.09%. Additionally, the stock is trading below all its moving averages, indicating a bearish trend. Despite a rise in delivery volume by 185.71% on 23 September, the stock's erratic trading pattern, with no trades on 5 out of the last 20 days, suggests a lack of consistent investor interest.<BR><BR>Broader market context indicates that while Fabino Enterprises has remained flat in the short term, the benchmark Sensex has gained 1.69% over the past week and 1.19% over the past month. This stark contrast highlights the stock's underperformance relative to the broader market. The year-to-date and one-year returns further emphasize this trend, with Fabino Enterprises down -30.09% and -17.86%, respectively, while the Sensex has seen gains of 8.72% and 9.50%. This broader market strength, coupled with the company's recent struggles, contributes to the perception of Fabino Enterprises as a less favorable investment at this time.